Disease · MONDO_0005961
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bacitracin vs Saline: deaths from any cause | 0 of 113 | 0 of 113 | 226 | NCT01222832 | Trial comparisons |
| Bacitracin vs Saline: Rate of Infection | 113 of 113 | 113 of 113 | 226 | NCT01222832 | Trial comparisons |
| Bacitracin vs Saline: serious adverse events | 0 of 113 | 0 of 113 | 226 | NCT01222832 | Trial comparisons |
| Dupilumab vs Placebo: deaths from any cause | 0 of 33 | 0 of 28 | 61 | NCT04684524 | Trial comparisons |
| Dupilumab vs Placebo: serious adverse events | 0 of 33 | 3 of 28 | 61 | NCT04684524 | Trial comparisons |
| Dupilumab 300 mg QW vs Placebo: deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT01920893 | Trial comparisons |
| Dupilumab 300 mg QW vs Placebo: serious adverse events | 2 of 30 | 4 of 30 | 60 | NCT01920893 | Trial comparisons |
| Dupilumab vs Placebo: Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) to Dupilumab | 1 of 22 | 0 of 19 | 41 | NCT04684524 | Trial comparisons |
| Xolair (Omalizumab) vs Xolair Placebo: deaths from any cause | 0 of 13 | 0 of 14 | 27 | NCT01066104 | Trial comparisons |
| Xolair (Omalizumab) vs Xolair Placebo: serious adverse events | 0 of 13 | 0 of 14 | 27 | NCT01066104 | Trial comparisons |
| Oral Placebo With Nebulized Intranasal Levofloxacin vs Oral Antibiotics With Nebulized Intranasal Placebo: deaths from any cause | 0 of 12 | 0 of 13 | 25 | NCT01988779 | Trial comparisons |
| Oral Placebo With Nebulized Intranasal Levofloxacin vs Oral Antibiotics With Nebulized Intranasal Placebo: serious adverse events | 0 of 12 | 0 of 13 | 25 | NCT01988779 | Trial comparisons |
| Oral Placebo With Nebulized Intranasal Levofloxacin vs Oral Antibiotics With Nebulized Intranasal Placebo: Number of Participants With Post-treatment Culture Negativity | 5 of 9 | 2 of 11 | 20 | NCT01988779 | Trial comparisons |
| Pulmozyme vs Placebo: serious adverse events | 1 of 8 | 2 of 8 | 16 | NCT00416182 | Trial comparisons |
| Mometasone 1mg vs Mometasone 2mg: deaths from any cause | 0 of 2 | 0 of 14 | 16 | NCT03979209 | Trial comparisons |
| Mometasone 1mg vs Mometasone 2mg: serious adverse events | 0 of 2 | 0 of 14 | 16 | NCT03979209 | Trial comparisons |
| Dupilumab vs Placebo: deaths from any cause | 0 of 3 | 0 of 2 | 5 | NCT05545072 | Trial comparisons |
| Dupilumab vs Placebo: serious adverse events | 0 of 3 | 0 of 2 | 5 | NCT05545072 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005961/comparisons